98963-12-3 Usage
Description
5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is a chemical compound characterized by its molecular formula C9H8BrNO2. It is a white solid that features a five-membered oxazolidinone ring with a bromomethyl substituent and a phenyl group. 5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is utilized in organic synthesis and pharmaceutical research, offering potential in the development of new drugs and as a building block for synthesizing other organic compounds. The presence of a bromine atom and the oxazolidinone ring endows this compound with versatility for the preparation of various biologically active molecules. However, due to its potential reactivity and health hazards, careful handling is advised.
Uses
Used in Pharmaceutical Research:
5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is used as a key intermediate in pharmaceutical research for the development of new drugs. Its unique structure allows for the creation of a variety of biologically active molecules, making it a valuable asset in the discovery and synthesis of novel therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is used as a building block for the synthesis of other organic compounds. Its bromomethyl group and oxazolidinone ring provide a foundation for the construction of complex organic molecules, facilitating the advancement of chemical research and development.
Used in Drug Development:
5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is employed as a versatile intermediate in the preparation of various biologically active molecules for drug development. Its chemical properties enable the design and synthesis of innovative pharmaceuticals with potential therapeutic applications.
Used in Chemical Research:
In the realm of chemical research, 5-(Bromomethyl)-3-phenyl-1,3-oxazolidin-2-one is used to explore new chemical reactions and mechanisms. Its reactivity and structural features make it an interesting subject for study, contributing to the broader understanding of chemical processes and the development of new synthetic methods.
Check Digit Verification of cas no
The CAS Registry Mumber 98963-12-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,8,9,6 and 3 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 98963-12:
(7*9)+(6*8)+(5*9)+(4*6)+(3*3)+(2*1)+(1*2)=193
193 % 10 = 3
So 98963-12-3 is a valid CAS Registry Number.
98963-12-3Relevant articles and documents
Direct synthesis of oxazolidin-2-ones from tert-butyl allylcarbamate via halo-induced cyclisation
Paisuwan, Waroton,Chantra, Thanakrit,Rashatasakhon, Paitoon,Sukwattanasinitt, Mongkol,Ajavakom, Anawat
, p. 3363 - 3367 (2017/05/22)
A novel synthetic pathway towards the 2-oxazolidinone derivatives involving the halo-induced cyclisation of tert-butyl allyl(phenyl)carbamate was successfully developed. Various halogenating reagents were evaluated under different reaction conditions for the reaction optimisation. Interestingly, the synthetic route to 2-oxazolidinone derivatives containing one halogen atom in the aliphatic site or two halogen atoms including the extra halogen atom substituted in the aryl group at the para position, were thoroughly established for all chloro-, bromo- and iodo compounds. Either halo-unsubstituted-aryl oxazolidinone or p-halo-substituted-aryl oxazolidinone could be selectively produced by selecting the appropriate choices of halogenated reagents and reaction conditions e.g. reaction time and temperature. Toloxatone, a commercial antidepressant, was successfully synthesized by using this developed method.
Synthesis of triazole-oxazolidinones via a one-pot reaction and evaluation of their antimicrobial activity
Demaray, Jeffrey A.,Thuener, Jason E.,Dawson, Matthew N.,Sucheck, Steven J.
supporting information; experimental part, p. 4868 - 4871 (2009/05/27)
C-5-substituted triazole-oxazolidinones were synthesized using a bromide catalyzed cycloaddition between aryl isocyanates and epibromohydrin followed by a three-component Huisgen cycloaddition. The library of compounds was screened for antibacterial activity against Mycobacterium smegmatis ATCC 14468, Bacillus subtilis ATCC 6633, and Enterococcus faecalis ATCC 29212. Notably, the 3-(4-acetyl-phenyl)-5-(1H-1,2,3-triazol-1-yl)methyl)-oxazolidin-2-one (18) showed an MIC of 1 μg/mL against M. smegmatis ATCC 14468, fourfold lower than the MIC measured for isoniazid.
